T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Clinical trials for T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for hard-to-treat lymphoma: three-drug combo enters early trials
Disease control Not yet recruitingThis early-phase trial tests whether combining three drugs (golcadomide, poseltinib, and rituximab) can shrink or control tumors in people with relapsed or refractory large B-cell lymphoma. About 20 adults will take part. The goal is to see if the combination works better than cu…
Matched conditions: T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 18, 2026 11:48 UTC
-
New drug combo aims to boost lymphoma treatment
Disease control Not yet recruitingThis study tests a new drug, epcoritamab, added to standard chemotherapy (R-CHOP) for people newly diagnosed with aggressive B-cell lymphoma. The main goal is to check safety, especially a side effect called cytokine release syndrome. About 20 adults will join this early-phase tr…
Matched conditions: T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Mwanasha Merrill, MD • Aim: Disease control
Last updated Jun 17, 2026 12:07 UTC